Thursday, July 9, 2015

10 Best Income Stocks For 2016

10 Best Income Stocks For 2016: Chimerix Inc (CMRX)

Chimerix, Inc., incorporated on April, 07, 2000, is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens.

CMX001 is an orally administered drug that utilizes its lipid technology to deliver intracellular concentrations of a potent antiviral compound, cidofovir-diphosphate (CDV-PP). Following oral dosing, CMX001 is absorbed through the gut, remains intact in the plasma, and is readily taken up by and delivered into cells. Once inside cells, CMX001 is converted into CDV-PP, which acts as an alternative substrate in a replicating virus. CMX001 is similar to the drug cidofovir in that both drug s are converted into CDV-PP once inside cells. Although cidofovir is approved for administration in an intravenous formulation, Vistide, it requires a plasma concentration to deliver a therapeutic level of cidofovir into cells and its use is limited due to the risk of kidney damage.

CMX157, Its second clinical stage compound, is an oral nucleotide compound in Phase 1 development for the treatment of human immunodeficiency virus (HIV) infection. In July 2012, the Company granted Merck an exclusive worldwide license to develop and commercialize CMX157 for all human uses. Merck is responsible for all development and marketing activities for CMX157 on a worldwide basis.

Advisors' Opinion:
  • [By Ben Levisohn]

    Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [th! e Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira (TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”

  • source from Top Stocks For 2015:

No comments:

Post a Comment